Riskpilot← Back to searchSign inGet full accessAlfamedica AB
ABActiveOrg 5593289589Gärdes Backe 1 BMedical specialists activities · NACE 8622Est. 20211-4 employees
Revenue 2024
SEK 1M
+44% vs 2023
EBITDA margin
-2.4%
+81% vs 2023
Equity ratio
5.1%
Financial strength
Net profit 2024
SEK -25K
+81% vs 2023
| Revenue | SEK 1M | +44% |
| EBITDA | SEK -24K | +81% |
| Net profit | SEK -25K | +81% |
| Total assets | SEK 250K | +557% |
| Equity | SEK 13K | +113% |
| Employees | — | — |
Legal name
Alfamedica AB
Org number
5593289589
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
28 juli 2021
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva läkarverksamhet, äga och förvalta värdepapper samt därmed förenlig verksamhet. Bolaget skall även bedriva skönhetsvård, utveckling och drift av massage- och SPA-verksamhet, frisk- och hälsovård, försäljning av friskvårdsutrustning samt sport-, hälso-, hud- och kroppsvårds- produkter, utbildningsverksamhet och konsultverksamhet inom skönhet och hälsa, uthyrning av lokal samt därmed förenlig verksamhet.
Address
Gärdes Backe 1 B
Email
nataliya.alegrund@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 779 | 698 | 1 001 |
| Staff expenses | −489 | −650 | −651 |
| EBITDA | 5 | −130 | −24 |
| Depreciation & amort. | — | — | — |
| EBIT | 5 | −130 | −24 |
| Net financials | 0 | 0 | −1 |
| Profit before tax | 5 | −130 | −25 |
| Tax | — | — | — |
| Net profit | 5 | −130 | −25 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 225 | 38 | 250 |
| Equity | 29 | −101 | 13 |
| Long-term debt | — | — | — |
| Short-term debt | 196 | 139 | 237 |
| Total debt | 196 | 139 | 237 |
EBITDA margin
-2.4%
This company
15.8%
Market median
-115% vs market
20222024
Equity ratio
5.1%
This company
38.2%
Market median
-87% vs market
20222024
Return on equity
-198.2%
This company
18.4%
Market median
-1177% vs market
20222024
Net profit margin
-2.5%
This company
8.1%
Market median
-131% vs market
20222024
Asset turnover
4.01×
This company
1.12×
Market median
+258% vs market
20222024
Debt / equity
18.66×
This company
0.62×
Market median
-2910% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
NA Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
JA Chief Executive Officer | Chief Executive Officer | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Alfamedica AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jurij Alegrund | Chief Executive Officer | 0 companies |
| Nataliya Alegrund | Chief Executive Officer | 0 companies |
| Alexandra Carolina Charlotta Fallvik | Deputy Board Member | 0 companies |